



Epidemiology, Antifungal Resistance and Therapy in Fungal Infection

Guest Editors:

Dr. Eduardo Alvarez Duarte

Unidad de Micología, Programa de microbiología y micología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile

Dr. Valentina Salas

Laboratorio Referencia Micología Médica, Instituto de Salud Pública de Chile, Región Metropolitana, Chile

Prof. Dr. Paulo Murilo Neufeld

Departamento de Análises Clínicas e Toxicológicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil

Deadline for manuscript submissions:

31 October 2024

Message from the Guest Editors

Dear Colleagues,

Fungal infections have been increasing globally. Many of them are becoming a serious threat to human life, either because of intrinsic resistance, acquired resistance, difficult access to mycological diagnosis or lack of knowledge of the aetiological agents in a given region. Several of the above-mentioned factors were taken into account to elaborate the WHO list of fungal pathogens of importance published in 2022. This list classified fungi into critical, high and medium priority. Given the above, we believe it is important to provide data on the epidemiology and antifungal resistance/therapy on a global level. Hence, we cordially invite you all to contribute your articles to this Special Issue.

Dr. Eduardo Alvarez Duarte

Dr. Valentina Salas

Prof. Dr. Paulo Murilo Neufeld

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi